Mesoblast (NASDAQ:MESO) Stock Price Crosses Below Fifty Day Moving Average – What’s Next?

Mesoblast Limited (NASDAQ:MESO) shares passed below its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $15.03 and traded as low as $14.45. Mesoblast shares last traded at $14.76, with a volume of 231,972 shares changing hands.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Mesoblast in a research report on Tuesday, April 21st. One research analyst has rated the stock with a Strong Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold”.

Mesoblast Stock Up 0.7%

The company has a debt-to-equity ratio of 0.10, a quick ratio of 1.41 and a current ratio of 1.58. The company has a market capitalization of $1.91 billion, a PE ratio of -27.33 and a beta of 2.09. The firm’s 50-day simple moving average is $15.03 and its 200 day simple moving average is $16.41.

Mesoblast (NASDAQ:MESO) last announced its quarterly earnings results on Thursday, January 29th. The company reported ($0.16) earnings per share (EPS) for the quarter. The firm had revenue of $25.67 million for the quarter. As a group, equities research analysts forecast that Mesoblast Limited will post -0.49 earnings per share for the current year.

Insider Transactions at Mesoblast

In related news, Director Gregory George bought 4,000,000 shares of the company’s stock in a transaction on Saturday, April 4th. The stock was bought at an average cost of $1.42 per share, with a total value of $5,680,000.00. Following the completion of the acquisition, the director owned 12,000,000 shares in the company, valued at approximately $17,040,000. This represents a 50.00% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders have bought 9,892,852 shares of company stock valued at $28,429,183 over the last three months. Company insiders own 18.80% of the company’s stock.

Institutional Investors Weigh In On Mesoblast

A number of institutional investors and hedge funds have recently modified their holdings of MESO. Rialto Wealth Management LLC acquired a new position in Mesoblast during the fourth quarter worth $839,000. JPMorgan Chase & Co. grew its holdings in Mesoblast by 55.6% in the third quarter. JPMorgan Chase & Co. now owns 2,831 shares of the company’s stock valued at $46,000 after purchasing an additional 1,012 shares during the last quarter. JFS Wealth Advisors LLC acquired a new stake in Mesoblast in the third quarter valued at $54,000. Vanguard Personalized Indexing Management LLC increased its position in shares of Mesoblast by 5.4% in the third quarter. Vanguard Personalized Indexing Management LLC now owns 14,047 shares of the company’s stock valued at $226,000 after buying an additional 716 shares in the last quarter. Finally, Royal Bank of Canada raised its stake in shares of Mesoblast by 22.5% during the 1st quarter. Royal Bank of Canada now owns 26,266 shares of the company’s stock worth $404,000 after buying an additional 4,827 shares during the last quarter. Institutional investors and hedge funds own 1.43% of the company’s stock.

Mesoblast Company Profile

Mesoblast Limited is a global leader in allogeneic cellular medicines, focused on developing treatments for inflammatory and immunologic diseases. Founded in 2004 by Dr. Silviu Itescu, the company builds on proprietary mesenchymal lineage cell technology to create off-the-shelf, donor-derived therapies. These therapies are designed to modulate immune responses and promote tissue repair in conditions where existing medical options are limited or ineffective.

The company’s most advanced product, Alofisel® (darvadstrocel), has been approved in Europe for the treatment of complex perianal fistulas in adults with Crohn’s disease.